На главную
Результаты поиска “Immunotherapy clinical studies and ovarian cancer”
Ovarian Cancer Clinical Trial to Study Immunotherapy Drug Combination
 
02:16
Roswell Park Cancer Institute has started a new, unique clinical trial investigating immunotherapy for patients with advanced ovarian cancer. Dr. Emese Zsiros, the study's Principal Investigator, explains the hope behind combining pembrolizumab (Keytruda) with intravenous bevacizumab (Avastin) and oral cyclophosphamide (Cytoxan). Read more: https://goo.gl/QenHYB
Просмотров: 607 Roswell Park Comprehensive Cancer Center
Cancer Patients Share Their Experience With Immunotherapy Clinical Trials
 
35:55
In this webinar for cancer patients and caregivers, we talk with people who have participated in cancer immunotherapy clinical trials. Our panel--which includes KayEllen, ovarian cancer survivor, and her daughter and caregiver, Nicole; T.J., melanoma survivor; and Emily, breast cancer survivor--share their experiences and insights. Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This series was made possible by the generous support of Genentech, LabAnswer and its employees, Celldex Therapeutics, and Regeneron. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.
Просмотров: 36098 Cancer Research Institute
Immunotherapy for Gynecological Cancers
 
54:48
This presentation summarizes the current progress in immunotherapy for ovarian, endometrial and cervical cancer. Recent clinical trial data will be reviewed, and promising novel therapeutic approaches will be discussed. Speaker: Oliver Dorigo, MD, PhD
Просмотров: 942 Stanford Health Care
Advances in Immunotherapy for Ovarian Cancer, with Dr  John Liao
 
43:38
Ovarian cancer often progresses before symptoms arise, resulting in too many late diagnoses. Given the risk of recurrence, it's important to have an effective second-line therapy for patients who relapse. Immunotherapy is a promising treatment for ovarian cancer is based on several lines of evidence. In this webinar, John B. Liao, M.D., Ph.D., will discuss the immunotherapy landscape for patients with ovarian cancer, and highlight the most effective immunotherapies currently available to patients as well as promising immune-based strategies that have the potential to benefit patients even more. John B. Liao, M.D., Ph.D., is an assistant professor of obstetrics and gynecology at the University of Washington School of Medicine as well as a practicing gynecologic oncologist affiliated with the Seattle Cancer Care Alliance. Dr. Liao specializes in treating women with gynecologic cancers including cervical, endometrial, and ovarian cancer. His goal is to achieve the best possible care for his patients by tailoring individual treatments and employing a multidisciplinary approach. In pursuit of that goal, he currently serves as the lead investigator of two clinical trials that are combining immunotherapy with chemotherapy to improve patient outcomes. The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, Genentech, Regeneron, and Advaxis.
Просмотров: 14463 Cancer Research Institute
Research to Advance Immunotherapy for Ovarian Cancer
 
00:54
Oliver Dorigo, MD, PhD, gynecologic oncologist, discusses new approaches under study at Stanford that harnesses the body’s own immune system in the fight against cancer. One promising area of research involves genetically modifying the patients’ white blood cells, called T cells, to enhance their ability to recognize and attack the cancer. Learn more at Care for Ovarian Cancer: Ovarian Cancer - https://stanfordhealthcare.org/medical-conditions/cancer/ovarian-cancer-ovarian-tumor.html Stanford Women’s Cancer Center - https://stanfordhealthcare.org/medical-clinics/womens-cancer-center.html Oliver Dorigo, MD, PhD - https://stanfordhealthcare.org/doctors/d/oliver-dorigo.html
Просмотров: 144 Stanford Health Care
Immunotherapy In Ovarian Cancer Treatment: Highlights Of What You Should Know
 
01:38
Dr. Kunle Odunsi, Chair, Department of Gynecologic Oncology The M. Steven Piver Professor of Gynecologic Oncology & Executive Director, Center for Immunotherapy, Roswell Park Cancer Institute discusses the role of immunotherapy and combination therapy in ovarian cancer, with Ovarcome. Talk About Ovarian Cancer. TOGETHER, we can Ovarcome!
Просмотров: 62 Ovarcome Non-Profit
Gynecologic Cancer Education: Immunotherapy & You
 
48:45
In May 2018, Mayo Clinic hosted a gynecologic cancer education course for ovarian cancer survivors and caregivers. Dr. Matthew Block, an immunologist, shared the latest on vaccine therapy and other immunotherapies to help with treatment and recurrence of cancer. He provided information about a number of clinical trials. To learn more about immunotherapy and clinical trials for cancer care, visit https://www.mayoclinic.org/departments-centers/oncology/home/orc-20198222
Просмотров: 280 Mayo Clinic
Shirley's Immunotherapy Story: After a Long Cancer Journey, a New Day with Immunotherapy
 
04:04
Shirley Dumont, of Southgate, Michigan, has had cancer more times than she can count. It started with breast cancer when she was just 39 years old, continued with ovarian and kidney cancer, and now at age 76 she is facing metastatic bladder cancer. After enduring debilitating chemotherapy and running out of conventional treatment options, Shirley’s doctor, Ulka Vaishampayan, M.D., at Karmanos Cancer Institute, recommended that she enroll in a clinical trial of an experimental immunotherapy drug. Called atezolizumab (made by Genentech/Roche), the drug belongs to a class of immune-enhancing medicines called checkpoint inhibitors. These are medicines that “release the brakes” on the immune system, allowing a stronger immune attack against cancer. The particular braking molecule targeted by atezolizumab is called PD-L1. The Cancer Research Institute is dedicated to funding the work of scientists who make immunotherapies like these possible. In this video, hear what immunotherapy has meant to Shirley and to her friends and family. To learn more, visit www.cancerresearch.org
Просмотров: 6149 Cancer Research Institute
Immunotherapy Clinical Trials: Sue Scott’s Story of Survival
 
04:59
An inside look at a Center for Cancer Research trial with Dr. Christian Hinrichs and his patient, Sue Scott. Dr. Hinrichs conducts basic and clinical research to discover and develop novel T-cell therapies for the treatment of patients with cancer. This work includes a clinical trial of HPV-targeted tumor-infiltrating T cells for patients with HPV+ cancers, which has demonstrated that this treatment can mediate complete regression of cervical cancer in some patients. Dr. Hinrichs' laboratory also has discovered genes for T-cell receptors that target HPV, and his group is testing new gene therapy treatments based on these receptors for patients with advanced HPV+ tumors. The Center for Cancer Research (CCR) is a part of the National Cancer Institute. For more on CCR: https://ccr.cancer.gov/ To search for clinical trials: http://trials.cancer.gov
Просмотров: 2526 National Cancer Institute
Current Advances in the Treatment Landscape of Ovarian Cancer
 
01:08
Mario M. Leitao, Jr, MD, FACOG, FACS, program director of Gynecologic Oncology at Memorial Sloan Kettering Cancer Center, discusses what is currently being investigated in the treatment landscape of ovarian cancers. There is a lot of discussion on hypothermic intraperitoneal chemotherapy (HIPEC), which is currently only available to patients on a clinical trial, Leitao says. HIPEC is currently being tested in a phase II trial at Memorial Sloan Kettering. Leitao says he hopes this can add value to patients as a treatment, but it does require more time. Leitao expects PARP inhibitors will head to the frontline setting for treatment of patients with ovarian cancer, though it is not there yet. His lab is currently running clinical trials on immunotherapies as a treatment in the neoadjuvant setting. He hopes to see if there is an improvement in survival or progression after adding immunotherapy drugs to platinum-paclitaxel based treatments. For more resources and information regarding anticancer targeted therapies in ovarian cancer: http://www.targetedonc.com/resource-center/ovarian
Просмотров: 78 Targeted Oncology
Dr. Coleman on Immunotherapy in Ovarian Cancer
 
01:35
Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in ovarian cancer.
Просмотров: 64 OncLiveTV
Health Professionals webinar: Future directions for ovarian cancer treatment- full
 
54:58
Ovarian Cancer Australia's Health Professional webinar 'Future Directions for Ovarian Cancer Treatment' was held on Friday June 30, 2017. With more than 8000 women in Australia currently living with ovarian cancer there is a lot of research still needed to ensure they receive the best possible treatments and outcomes. During this webinar Dr Tarek Meniawy presents the current evidence for immunotherapy in the treatment of ovarian cancer, how its use is being optimised through current and future clinical trials and combining immunotherapy with other anti-cancer treatments and personalised medicine to improve outcomes. He also discusses the pivotal trial leading to the licencing of olaparib (in Australia) including updated survival data. We also hear from Emma Burt, who was diagnosed with ovarian cancer in 2015 at the age of 32. Following multiple surgeries, chemotherapy and radiation treatment Emma began participating in an immunotherapy clinical trial that she discusses during this webinar.
Просмотров: 83 Ovarian Cancer Australia
Future Directions for Ovarian Cancer Treatment - Dr Tarek Meniawy
 
21:00
Dr Tarek Meniawy, medical oncologist and clinical senior lecturer, turns the spotlight on immunotherapy and its use in the treatment of ovarian cancer. Speaking at our April Future Directions forum, Dr Meniawy, takes a look at the evolution of ovarian cancer treatments, the historic transition from non-specific therapies that target multiple organ systems to the development of more targeted, personalised treatments, the evolution of immunotherapy, clinical trials of immunotherapy for ovarian cancer, and future directions for the use of immunotherapy and targeted treatments in treating ovarian cancer.
Просмотров: 664 Ovarian Cancer Australia
Dr. Joyce F. Liu on ovarian cancer clinical trial results | Dana-Farber Cancer Institute
 
02:16
In this video Dana-Farber's Joyce F. Liu talks about the results from a clinical trial she led where a novel antibody-guided drug achieved responses in platinum drug-resistant ovarian cancer. At Dana-Farber/Brigham and Women's Cancer Center, ovarian cancer is treated through the Susan F. Smith Center for Women's Cancers Gynecologic Oncology Program. Learn more about our program at: http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Gynecological-Cancer-Treatment-Center.aspx
Просмотров: 877 Dana-Farber Cancer Institute
ANZGOG's ovarian cancer immunotherapy clinical research
 
00:18
Immunotherapy is considered the next revolution for new treatments in ovarian cancer. Dr Tarek Meniawy, member of ANZGOG, is Primary Investigator on iPRIME, an ovarian cancer immunotherapy study. Funding for the translational substudy of iPRIME has been provided by the OASIS Alliance. Find out more at www.anzgog.org.au
Просмотров: 19 ANZGynaeOncGroup
KayEllen Gebhart's Cancer Immunotherapy Story
 
03:06
KayEllen was enrolled in a clinical trial of a therapeutic cancer vaccine for stage 3 ovarian cancer after searching for treatment options through the CRI website. The Answer to Cancer (TheA2C) caught up with KayEllen, who shared her cancer treatment story from diagnosis to remission. View KayEllen's complete story: http://www.theanswertocancer.org/online-community-for-cancer-immunotherapy/stories-from-patients-and-caregivers/kay-ellen-gebhart-patient-story/
Просмотров: 1276 the answer to cancer
Finding an Immunotherapy Clinical Trial, with Patrick Meins
 
51:24
What are clinical trials? When is a clinical trial right for me? How do I talk to my doctor about clinical trials? What information do I need to have—and what information do the clinical trial organizers need? There are so many questions surrounding clinical trials for both patients and caregivers that need to be answered in order to make the right choice. In this webinar, Patrick Meins, a Clinical Trial Navigator at EmergingMed, answers common questions around cancer clinical trials including trial definitions, eligibility criteria, and how to search for the right one. After receiving an MA in Spanish Philology and doing many odd jobs, Patrick Meins found his way into health care advocacy, starting with a local HIV/AIDS organization and moving on to working with the Cancer Information Service at the National Cancer Institute. In 2010, he began working as a Clinical Trials Navigator for cancer patients. He works with a wide range of patients, caregivers, and healthcare professionals to match to clinical trials that are specific to their own disease and treatment history. He has guided many through narrowing down trials that fit their needs. He is passionate about being able to help so many during these times. The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, with additional support from Regeneron, Sanofi Genzyme, and Adaptimmune.
Просмотров: 9468 Cancer Research Institute
Potential for Immunotherapy in Ovarian Cancer
 
06:18
Panelists Bradley J. Monk, MD; Katie Moore, MD; Gottfried E. Konecny, MD; and Robert L. Coleman, MD, discuss the ongoing research looking at checkpoint inhibitors in multiple settings for patients with ovarian cancer.
Просмотров: 1170 OncLiveTV
Immunotherapy clinical trial keeps melanoma survivor cancer-free
 
02:16
Karlee Steele had beaten melanoma twice, once in 2011 and again in 2013, so she was shocked when a year-and-a-half later, she found a swollen node under her arm. After a needle biopsy, she was told the cancer wasn’t outside her skin, but inside, in the nodes under her right arm. It was stage III melanoma. It originated from her second melanoma in 2013. It was so aggressive that it traveled into her lymph nodes where it stayed silent for almost two years. Karlee decided to have surgery at MD Anderson. Following surgery, she enrolled in an immunotherapy vaccine clinical trial. Over time, the immunotherapy worked, gradually shrinking and ultimately eliminating the melanoma. Today, Karlee is cancer-free, no longer in treatment and grateful to have her life back. She credits MD Anderson's Melanoma Moon Shot Program as the driving force to choosing MD Anderson. Read more about Karlee https://www.mdanderson.org/publications/cancerwise/2016/11/melanoma-immunotherapy-clinical-trial.html. Request an appointment at MD Anderson by calling 1-877-632-6789 or online at: https://my.mdanderson.org/RequestAppointment?cmpid=youtube_appointment_melanoma_clinicaltrial
Просмотров: 621 MD Anderson Cancer Center
Recurrent Ovarian Cancer and Clinical Trials
 
05:22
Dr. Bill Cliby and Dr. Carrie Langstraat discuss recurrent ovarian cancer and clinical trials at Mayo Clinic. To learn more, visit http://www.mayoclinic.org/diseases-conditions/ovarian-cancer/care-at-mayo-clinic/clinical-trials/con-20028096?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504
Просмотров: 609 Mayo Clinic
Ask a Scientist about Clinical Trials: How Is Treatment on a Clinical Trial Different
 
01:32
Every week in June 2017, as part of Cancer Immunotherapy Month, we will publish a response to patient questions from immunotherapy expert Dr. Michael Postow of Memorial Sloan Kettering Cancer Center. In this episode, Dr. Postow describes the differences in treatment on a clinical trial compared to standard cancer care. This series is made possible with generous support from Regeneron.
Просмотров: 931 Cancer Research Institute
Clinical Trials for Ovarian Cancer Patients
 
01:13
UW Health oncologist Lisa Barrolhiet describes a clinical trial designed for ovarian cancer patients.
Просмотров: 105 UW Health
Keeping Ovarian Cancer at Bay
 
05:16
Since her diagnosis with advanced ovarian cancer in 2010, Teri Woodhull participated in cancer clinical trials to keep the disease in check. “Although this treatment is not a cure, it has kept the cancer at bay for more than two years,” she explains. Read Teri’s story and those of other survivors in the AACR Cancer Progress Report 2017 here: http://cancerprogressreport.org/Pages/cpr17-survivors.aspx.
Просмотров: 12119 American Association for Cancer Research
The Promise of Immunotherapy for Ovarian Cancer | Dana-Farber Cancer Institute
 
05:27
Panos Konstantinopoulos, MD, PhD, MMSc, presents at 2016 Susan F. Smith Center for Women's Cancers Executive Council Breakfast on Friday, April 8, 2016.
Просмотров: 754 Dana-Farber Cancer Institute
"Ovarian Cancer Research and You" presentation - New Treatments on the Horizon for Ovarian Cancer
 
48:19
Dr. Hal W. Hirte, MD, FRCP (C), Medical Oncologist, Juravinski Cancer Centre; Gynecologic Cancer Disease Site Co-Chair - Canadian Clinical Trials Group Dr. Hirte discusses the landscape of emerging research as it relates to new treatments. His presentation includes topics such as: • New opportunities • Blood vessel formation (angiogenesis) • DNA repair • Immune therapy • Intraperitoneal chemotherapy Dr. Hirte also speaks on clinical trial opportunities for patients/survivors.
Просмотров: 1244 OvarianCancerCanada
Novel Immunotherapy Targets Recurrent Ovarian Cancer
 
04:04
From the annual meeting of the American Association for Cancer Research in Washington, D.C.
Dr. Lana Kandalaft on a Novel Two-Step Immunotherapy for Ovarian Cancer
 
02:29
Lana Kandalaft, PharmD, MTR, PhD, director of clinical development in the Ovarian Cancer Research Center, University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer. For more resources on ovarian cancer, visit http://www.onclive.com/specialty/womens-cancer
Просмотров: 1492 OncLiveTV
TRACO 2017 - Ovarian Cancer in the Genomics Era and Immune checkpoints
 
01:50:04
TRACO 2017 - Ovarian Cancer in the Genomics Era and Immune checkpoints Air date: Monday, September 25, 2017, 4:00:00 PM Category: TRACO Runtime: 01:50:04 Description: Translational Research in Clinical Oncology (TRACO) Recent advances in understanding cancer biology are beginning to be translated into improvements in diagnosis and treatment of cancer. In the post-genome era, we increasingly rely on strong collaboration between basic and clinical scientists to develop novel approaches for treatment of human disease. The NCI Center for Cancer Research (CCR) is one of the largest cancer research organizations in the world, with more than 200 principal investigators, and has played a major role in developing and implementing many new technologies, such as nanotechnology, next generation sequencing, genomics and proteomics. For more information go to http://ccr.cancer.gov/trainee-resources-courses-workshops-traco Author: Christina M. Annunziata, MD, PhD, NCI, NIH and Stephanie L. Goff, M.D., NCI, NIH Permanent link: https://videocast.nih.gov/launch.asp?23483
Просмотров: 1272 nihvcast
Ovarian Cancer: Enrolling in Clinical Trials
 
04:05
Kathleen Moore, MD, emphasizes the importance of enrolling patients with ovarian cancer onto clinical trials. In this segment, Dr. Moore describes which patients are the best candidates for PARP inhibitor therapy and why these and other patients will benefit from clinical trial participation.
Просмотров: 88 curetoday
Immunotherapy for Pancreatic Cancer
 
58:11
This webinar describes strategies to harness a patient's immune system to fight cancer and discusses progress in this area of research. The presentation also highlights the future of immunotherapy in pancreatic cancer and advancements in clinical trials. This webinar was recorded on June 13, 2016. The presenter is Robert H. Vonderheide, MD, DPhil – University of Pennsylvania. We would like to give a special thank you to our webinar sponsor – Lilly Oncology. For more information about pancreatic cancer or our free services, please email a Patient Central Associate at patientcentral@pancan.org, or call toll-free 877-467-0875. Associates are available Monday - Friday, 7 a.m. - 5 p.m. PT.
Просмотров: 3224 Pancreatic Cancer Action Network
Gynecologic Cancer: Clinical Trials
 
03:17
James Barter, MD, medical director, gynecologic oncology research, Holy Cross Health, discusses the latest gynecologic cancer clinical trials, including the new ovarian cancer vaccine study at Holy Cross Health.
Просмотров: 24 Holy Cross Health
"Ovarian Cancer Research and You" - Harnessing Viruses for Ovarian Cancer Immunovirotherapy
 
37:06
Dr. Evanthia Galanis, MD, Professor of Oncology, Mayo Clinic School of Medicine Dr. Galanis discusses a new method in ovarian cancer treatment that uses genetically-engineered viruses to selectively replicate and destroy cancer cells. She also explains how replication in cancer cells can generate “danger” signals that effectively activate antitumor immune responses. Current clinical trials and future directions are also reviewed.
Просмотров: 591 OvarianCancerCanada
Gynecologic oncology research at ASCO 2017: Ovarian cancer surgery trials
 
02:09
Giuseppe Del Priore, MD, from Morehouse University School of Medicine in Atlanta, GA, discusses two ovarian cancer trials conducted by the AGO Study Group in Germany: The LION study on lymphadenectomy in ovarian neoplasms; and AGO DESKTOP III/ENGOT ov20, which evaluates the impact of secondary cytoreductive surgery in recurrent ovarian cancer.
Просмотров: 635 Society of Gynecologic Oncology
Beating Cancer: Precision Immunotherapy
 
03:23
Beating cancer with precision immunotherapy is a goal for many cancer researchers. For the first time, a drug has been FDA-approved for cancer based on disease genetics rather than type. Developed from 30 years of basic research at Johns Hopkins and its Bloomberg~Kimmel Institute, pembroluzimab now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in so-called mismatch repair genes. Drs. Bert Vogelstein and Dung Le describe this research and its potential impact for people with cancer. Learn more about immunotherapy at http://www.hopkinsmedicine.org/kimmel_cancer_center/centers/bloomberg_kimmel_institute_for_cancer_immunotherapy/index.html
Просмотров: 1390 Johns Hopkins Medicine
Clinical Trials for Ovarian Cancer Vaccine
 
04:38
Dr. Pramod Srivastava, director of the Neag Comprehensive Cancer Center at UConn Health, is interviewed on NBC Connecticut about ovarian cancer. Srivastava has developed an ovarian cancer vaccine that uses a patient’s own immune response and is “custom-made” for each patient. Initial studies show it’s less toxic than current chemotherapy treatments and more targeted.
Просмотров: 1096 UConn Health
Immunotherapy In Ovarian Cancer: Hope or Hype?
 
22:38
Dr. Amir Jazaeri discusses the Role of Immunotherapy in Ovarian Cancer: Hope or Hype? at the Ovarcome Annual ZEAL FOR TEAL Luncheon, 2017.
Просмотров: 143 Ovarcome Non-Profit
PARP Inhibitors and Ovarian Cancer | Memorial Sloan Kettering
 
17:17
To learn more about ovarian cancer treatments, please visit http://www.mskcc.org/ovariancancer Learn about MSK: https://www.mskcc.org CONNECT WITH MSK Facebook: http://facebook.com/sloankettering Twitter: http://twitter.com/sloan_kettering Instagram: http://instagram.com/sloankettering Request an appointment at MSK by calling 800-525-2225 or online at: https://www.mskcc.org/appointments/request-appointment Medical oncologist Katherine Bell-McGuinn describes a novel class of ovarian cancer therapies called PARP inhibitors. These drugs, which are in development at Memorial Sloan Kettering Cancer Center, are designed to block a protein called PARP that causes tumor cells to grow uncontrollably. (In normal cells, PARP helps repair damaged DNA.) This approach could help the 10% of patients who have deficiencies in another protein called BRCA, which is also involved in DNA repair, and whose cells therefore rely more heavily on PARP to repair DNA breaks within tumor cells. {partial transcript} As Carol mentioned, I will focus on PARP inhibitors, one of the new classes of therapies that have hit the ovarian cancer clinic in the last two-to-three years and share with you why we are trying to target this for a therapy for ovarian cancer. I’ll share with you some of the initial results we’ve seen in the laboratory and in patients as well as update you on what we are doing here and what clinical trials are available for our patients. As part of running these studies, we do receive support here at Memorial Sloan Kettering from Astra Zeneca and BiPar, which are two of the companies that we are working with. We are going to talk about the rationale for these agents. Why target PARP? What is PARP? What does it do in the cell? We are also going to talk about which patients can benefit from these drugs, specifically BCR patients. We are also going to talk about laboratory models and clinical studies that have gone on. Finally, we are going to talk about where we are now, and where we are going.
Просмотров: 6697 Memorial Sloan Kettering
How Do Cancer Clinical Trials Work and Should You Participate?
 
02:49
Many new cancer treatments, drugs and cancer research stem from clinical trials, which are research studies to determine the effectiveness of a particular cancer treatment. In this video, oncologist Dr. Stephen Lemon explains how #clinicaltrials work, including different trial phases, and how cancer patients may choose to volunteer for these studies, based upon their eligibility criteria. Visit http://www.oacancer.com/clinical-trials-for-cancer/ to learn more about clinical trials for cancer. #drstephenlemon #CancerResearch Dr Stephen Lemon is medical oncologist who now practices at Overlake Cancer Center Bellevue WA. He produces cancer information videos and web related cancer education projects. He invites you to follow his ongoing work at https://www.lightersideofcancer.com/
Просмотров: 1987 Oncology Associates
Advantages of Ovarian Cancer Clinical Trials - "WORDs Of Wisdom" Dr. Bradley J. Monk
 
01:53
"WORDs of Wisdom" video series: Dr. Bradley J. Monk explains the advantages of participating in a clinical trial for ovarian cancer treatment. Produced by: WORDonCancer.org
Просмотров: 384 wordoncancer
NY-ESO-1 immunotherapy for ovarian cancer
 
09:01
Dr Kunle Odunsi talks to ecancertv at AACR2016 about his research into courses of immunotherapy against ovarian cancer. Having established in previous research the link between T cell infiltration of a tumour to improved patient survival, Dr Odunsi has sought to determine an ovarian cancer antigen - in this case NY-ESO-1 - to prolong patient remission and promote anti-tumour immune response in patients. Historically, cancer cells have evaded immune response via manipulation of cellular checkpoints PD1 and IDO, which limits T cell proliferation. By combining these targets with CAR-T cell technologies, Dr Odunsi hopes to extend T cell lifespans in patients, and provide a long-lasting anti-tumour effector T cell population.
Просмотров: 382 ecancer
Patient Perspective: Benefiting from Clinical Trials – NYC Immunotherapy Patient Summit 2017
 
38:13
Our cancer patient panel—Kristin (treated for leukemia), Philip (treated for kidney cancer), and Joanna (caregiver to her husband with prostate cancer)—shared their experiences participating in immunotherapy clinical trials at the Immunotherapy Patient Summit in New York. http://www.cancerresearch.org/summit Meet the participants Kristin Kleinhofer was diagnosed with acute lymphoblastic leukemia (ALL) and started a two-year journey with chemotherapy. That treatment failed to keep Kristin in remission. By 2014 her cancer was back, this time Kristin enrolled in a clinical trial of chimeric antigen receptor T-cell (CAR T) therapy. She was one of the first patients to benefit from this cancer treatment and today, Kristin remains cancer free. Back in 2012, Philip Prichard received news that he had a 3.8 pound cancer tumor on his right kidney. The tumor was successfully removed but months later the cancer had returned and spread to his lungs and liver. Philip and his wife Susan were not satisfied with the chemo options presented to them. Instead they researched other treatment options and came across a clinical trial for nivolumab. Around the third month in this trial, Philip’s main tumor had shrunk, and by spring of 2015, his tumors were undetectable. Today, Philip is healthy and wants patients to remain hopeful. Johanna Sedman’s husband Andy was diagnosed with advanced prostate cancer in 2014. Johanna began researching all treatment options available, which led to an immunotherapy clinical trial of ipilimumab. Following chemotherapy and surgery, Andy participated in the trial. He credits Johanna for helping find the best options available at a time when he felt overwhelmed. While Andy has had some progression of his PSA, he feels good and remains active.
Просмотров: 178 Cancer Research Institute
Steven O'Day MD Discusses Biothera Clinical Trial in Melanoma & TNBC
 
03:08
Renowned oncologist and melanoma specialist Steven O'Day, MD, talks about the potential synergies of combining Biothera Pharmaceuticals' developmental cancer immunotherapy, Imprime PGG, and Merck's checkpoint inhibitor therapy, KEYTRUDA (pembrolizumab), in Biothera's Phase 2 melanoma/triple negative breast cancer study. Dr. O’Day, Professor of Medical Oncology and Director of Immuno-Oncology and Clinical Research, The John Wayne Cancer Institute at Providence Saint John’s Health Center, is a Principal Investigator for this study and Chairman of the Trial Steering Committee overseeing the clinical trial.
Просмотров: 1361 Biothera Pharmaceuticals, Inc.
Biomarkers in Cancer Immunotherapy: How Much Do They Matter?
 
42:53
If you're a patient interested in receiving cancer immunotherapy, you might hear the word "biomarkers" come up. They are an increasingly important area of study within the field of cancer immunotherapy research. These biological "signals" provide many clues for doctors to help them identify which patients are more likely to benefit from treatment and the duration of that benefit. In this webinar for patients and caregivers, Dr. Haidong Dong of the Mayo Clinic, discusses the role biomarkers play in making treatment decisions, and delves into the latest research to identify new biomarkers. This webinar was recorded Tuesday, August 29, 2017. The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, Genentech, Regeneron, and Advaxis. Browse our Cancer Immunotherapy and You Webinar Series playlist here on YouTube to see other webinars in this series.
Просмотров: 18584 Cancer Research Institute
ESMO 2018 Congress: Highlights in advanced ovarian cancer
 
01:56
Prof. Nicoletta Colombo reports on key results from ESMO 2018 Congress: LBA7_PR: Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation: Phase III SOLO1 trial. Produced by the European Society for Medical Oncology http://www.esmo.org
Просмотров: 1245 European Society for Medical Oncology
Dr. Moore on Challenges With Immunotherapy in Ovarian Cancer
 
01:34
In general, immunotherapy is well tolerated. However, there are significant toxicities that occur that providers need to be mindful of because the responses to them are different than other agents. There are ongoing studies with immune checkpoint inhibitors, so the education is out there and we are meeting that safety bar now. That is the same with any new agent. It is important to manage the safety for our patients, which is true across all solid tumors. The biggest challenge is identifying whether this a class of drugs that belongs in our treatment paradigm. I hope the answer is “yes,” since there are many options for targeting the immune system. We are using PD-1/PD-L1 and CTLA-4 inhibitors, but there is a pipeline of agents that are different checkpoint modulators. Even different ways to target different parts of the immune system are important. It may be that checkpoint inhibitors aren't the way that we should be targeting ovarian cancer for immune response, but there could be other effective ways to do it.
Просмотров: 64 OncLiveTV
Clinical trial was the right choice for lung cancer survivor
 
02:15
When Georgia Dominick was diagnosed with stage IV metastatic lung cancer in Aug. 2014, an Alabama oncologist told her she only had a year left to live. But Georgia didn’t accept that prognosis and came to MD Anderson instead. Here, she took part in a clinical trial involving a new immunotherapy drug for people with her exact type of cancer. She is now two years post-diagnosis, and is considered in remission. “If I had the choice of going anywhere else in the world for free, I would stay right here,” she says. MD Anderson offers many clinical trials for all different cancers. To learn more about clinical trials and search for clinical trials, visit https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials.html
Просмотров: 987 MD Anderson Cancer Center